Business
LENSAR develops and markets laser systems and consumables for cataract surgery and astigmatism management.
LENSAR grew cataract-laser revenue but losses and cash burn remained large, showing that commercial adoption has not yet covered the cost of its installed platform.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 12.4%OK
- Profitability — The net loss widened from $31.404M to $34.28MWatch
- Cash flow — Free cash flow remained negative, with the outflow widening from $2.431M to $14.914MWatch
- Margins — Operating margin contracted 2438 bps to -47.58%Watch
- Accounting — Commercial growth without operating leverageWatch
- Insiders — 0 purchases and 0 salesNote
Where the revenue comes from
Fiscal 2025, as LENSAR, Inc. reports it. History and quarterly detail are in the app.
- Product$45.9M
- Service$5.7M
Leadership changes
From LENSAR, Inc.'s own filings, the day they're filed.
- Michael A. Rossi · Chief Financial Officer · appointmenteff. 2026-05-29
- John P. McLaughlin · Directors · departureeff. 2023-10-31
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-10
- DEF 14A · Annual proxy (pay & governance)2026-06-23
- 8-K · Company announcement2026-05-29
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about LENSAR, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.